|
1.
|
Rubin BP, Heinrich MC and Corless CL:
Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: review on morphology, molecular pathology,
prognosis, and differential diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
3.
|
Hirota S, Isozaki K, Moriyama Y, et al:
Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Heinrich MC, Corless CL, Demetri GD, et
al: Kinase mutations and imatinib response in patients with
metastatic gastrointestinal stromal tumor. J Clin Oncol.
21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Heinrich MC, Corless CL, Duensing A, et
al: PDGFRA activating mutations in gastrointestinal stromal tumors.
Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Tran T, Davila JA and El-Serag HB: The
epidemiology of malignant gastrointestinal stromal tumors: an
analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol.
100:162–168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Demetri GD, von Mehren M, Blanke CD, et
al: Efficacy and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors. N Engl J Med. 347:472–480. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Akwari OE, Dozois RR, Weiland LH and
Beahrs OH: Leiomyosarcoma of the small and large bowel. Cancer.
42:1375–1384. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Shiu MH, Farr GH, Papachristou DN and
Hajdu SI: Myosarcomas of the stomach: natural history, prognostic
factors and management. Cancer. 49:177–187. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
McGrath PC, Neifeld JP, Lawrence W Jr, Kay
S, Horsley JS 3rd and Parker GA: Gastrointestinal sarcomas.
Analysis of prognostic factors. Ann Surg. 206:706–710. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ng EH, Pollock RE, Munsell MF, Atkinson EN
and Romsdahl MM: Prognostic factors influencing survival in
gastrointestinal leiomyosarcomas. Implications for surgical
management and staging. Ann Surg. 215:68–77. 1992. View Article : Google Scholar
|
|
12.
|
Druker BJ, Tamura S, Buchdunger E, et al:
Effects of a selective inhibitor of the Abl tyrosine kinase on the
growth of Bcr-Abl positive cells. Nat Med. 2:561–566. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Buchdunger E, Cioffi CL, Law N, et al: Abl
protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal
transduction mediated by c-kit and platelet-derived growth factor
receptors. J Pharmacol Exp Ther. 295:139–145. 2000.
|
|
14.
|
Heinrich MC, Griffith DJ, Druker BJ, Wait
CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine
kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood. 96:925–932. 2000.PubMed/NCBI
|
|
15.
|
Wang WL, Healy ME, Sattler M, et al:
Growth inhibition and modulation of kinase pathways of small cell
lung cancer cell lines by the novel tyrosine kinase inhibitor STI
571. Oncogene. 19:3521–3528. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Yeh CN, Chen TW, Wu TJ, Hsueh S and Jan
YY: Treatment of patients with advanced gastrointestinal stromal
tumor of small bowel: implications of imatinib mesylate. World J
Gastroenterol. 12:3760–3765. 2006.PubMed/NCBI
|
|
17.
|
Yeh CN, Chen TW, Lee HL, et al: Kinase
mutations and imatinib mesylate response for 64 Taiwanese with
advanced GIST: preliminary experience from Chang Gung Memorial
Hospital. Ann Surg Oncol. 14:1123–1128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Chen YY, Yeh CN, Cheng CT, et al:
Sunitinib for Taiwanese patients with gastrointestinal stromal
tumor after imatinib treatment failure or intolerance. World J
Gastroenterol. 17:2113–2119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Rutkowski P, Debiec-Rychter M and Ruka W:
Gastrointestinal stromal tumors: key to diagnosis and choice of
therapy. Mol Diagn Ther. 12:131–143. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Osusky KL, Hallahan DE, Fu A, et al: The
receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell
migration, tubule formation, and blood vessel formation in vivo,
but has little effect on existing tumor vessels. Angiogenesis.
7:225–233. 2004. View Article : Google Scholar
|
|
21.
|
Abrams TJ, Lee LB, Murray LJ, Pryer NK and
Cherrington JM: SU11248 inhibits KIT and platelet-derived growth
factor receptor beta in preclinical models of human small cell lung
cancer. Mol Cancer Ther. 2:471–478. 2003.PubMed/NCBI
|
|
22.
|
Mendel DB, Laird AD, Xin X, et al: In vivo
antitumor activity of SU11248, a novel tyrosine kinase inhibitor
targeting vascular endothelial growth factor and platelet-derived
growth factor receptors: determination of a
pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res.
9:327–337. 2003.
|
|
23.
|
Murray LJ, Abrams TJ, Long KR, et al:
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an
experimental breast cancer bone metastasis model. Clin Exp
Metastasis. 20:757–766. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
O’Farrell AM, Abrams TJ, Yuen HA, et al:
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent
activity in vitro and in vivo. Blood. 101:3597–3605.
2003.PubMed/NCBI
|
|
25.
|
Schueneman AJ, Himmelfarb E, Geng L, et
al: SU11248 maintenance therapy prevents tumor regrowth after
fractionated irradiation of murine tumor models. Cancer Res.
63:4009–4016. 2003.PubMed/NCBI
|
|
26.
|
Heinrich MC, Marino-Enriquez A, Presnell
A, et al: Sorafenib inhibits many kinase mutations associated with
drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther.
11:1770–1780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kindler HL, Campbell NP, Wroblewski K, et
al: Sorafenib (SOR) in patients (pts) with imatinib (IM) and
sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors
(GIST): Final results of a University of Chicago Phase II
Consortium trial. J Clin Oncol (ASCO Meeting Proceedings).
29:100092011.
|
|
28.
|
Reichardt P, Montemurro M, Gelderblom H,
et al: Sorafenib fourth-line treatment in imatinib-, sunitinib-,
and nilotinib-resistant metastatic GIST: A retrospective analysis.
J Clin Oncol (2009 ASCO Annual Meeting). 27(15 Suppl): Abstract
10564,. 2009.
|
|
29.
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):
Soft Tissue Sarcoma. Version 2. 2012.www.NCCN.orghttps://www.NCCN.org. Accessed June 17,
2012.
|
|
30.
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
31.
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors - definition, clinical, histological,
immunohistochemical, and molecular genetic features and
differential diagnosis. Virchows Arch. 438:1–12. 2001. View Article : Google Scholar
|
|
32.
|
Fletcher CD, Berman JJ, Corless C, et al:
Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Verweij J, Casali PG, Zalcberg J, et al:
Progression-free survival in gastrointestinal stromal tumours with
high-dose imatinib: randomised trial. Lancet. 364:1127–1134. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Italiano A, Cioffi A, Coco P, et al:
Patterns of care, prognosis, and survival in patients with
metastatic gastrointestinal stromal tumors (GIST) refractory to
first-line imatinib and second-line sunitinib. Ann Surg Oncol.
19:1551–1559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Miettinen M, El-Rifai W, Sobin LH and
Lasota J: Evaluation of malignancy and prognosis of
gastrointestinal stromal tumors: a review. Hum Pathol. 33:478–483.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Nilsson B, Bümming P, Meis-Kindblom JM, et
al: Gastrointestinal stromal tumors: the incidence, prevalence,
clinical course, and prognostication in the preimatinib mesylate
era - a population-based study in western Sweden. Cancer.
103:821–829. 2005. View Article : Google Scholar
|
|
37.
|
Cao H, Zhang Y, Wang M, et al: Prognostic
analysis of patients with gastrointestinal stromal tumors: a single
unit experience with surgical treatment of primary disease. Chin
Med J (Engl). 123:131–136. 2010.PubMed/NCBI
|
|
38.
|
Keohan M, D’Adamo D, Qin L, et al:
Analysis of toxicity in a phase II study of sorafenib in soft
tissue sarcoma (STS). J Clin Oncol 2007 ASCO Annual Meeting
Proceedings (Post-Meeting Edition). 25(18 Suppl): 100612007.
|
